Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

10.43 -0.31 (-2.89%)
Delayed Quote Updated: 12:28 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Turn Therapeutics Inc. - Common Stock

News headline image
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Conversation Centered Around Healthcare Communications and Pandemic Preparedness 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research 
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Arthur Golden to Board of Directors
Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs 
From Turn Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.